about
Inherited platelet disorders: toward DNA-based diagnosisDefects in TRPM7 channel function deregulate thrombopoiesis through altered cellular Mg(2+) homeostasis and cytoskeletal architecture.Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality.Von Willebrand factor and angiogenesis: basic and applied issues.The diagnosis and management of von Willebrand disease: a United Kingdom Haemophilia Centre Doctors Organization guideline approved by the British Committee for Standards in Haematology.Site-specific analysis of von Willebrand factor O-glycosylation.Expanded repertoire of RASGRP2 variants responsible for platelet dysfunction and severe bleeding.New oral anticoagulants: their role and future.Specific treatment for cancer-associated thrombosis.Pharmacokinetics, phenotype and product choice in haemophilia B: how to strike a balance?Safety and pharmacokinetics of anti-TFPI antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial.Can you grow out of von Willebrand disease?International Society on Thrombosis and Haemostasis core curriculum project: core competencies in clinical thrombosis and hemostasis.Intracranial Hemorrhage and Early Mortality in Patients Receiving Extracorporeal Membrane Oxygenation for Severe Respiratory Failure.Genetically Determined FXI (Factor XI) Levels and Risk of StrokePhenotype description and response to thrombopoietin receptor agonist in -related disorderEvaluation of von Willebrand factor concentrates by platelet adhesion to collagen using an in vitro flow assayThe ADAMTS13-VWF axis is dysregulated in chronic thromboembolic pulmonary hypertensionUtility of fibrinogen in the coagulation screen.The top 10 research priorities in bleeding disorders: a James Lind Alliance Priority Setting PartnershipGenetically Determined Platelet Count and Risk of Cardiovascular DiseaseThe use of viscoelastic haemostatic assays in the management of major bleeding: A British Society for Haematology GuidelineUse of Antithrombin Concentrate for Acquired Antithrombin Deficiency in Acutely Unwell Children Receiving Unfractionated HeparinRecommendations for the clinical interpretation of genetic variants and presentation of results to patients with inherited bleeding disorders. A UK Haemophilia Centre Doctors' Organisation Good Practice PaperDiagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disordersMultiyear Follow-up of AAV5-hFVIII-SQ Gene Therapy for Hemophilia APathogenesis and Management of Thrombotic Disease in Myeloproliferative NeoplasmsLimitations on point care APTT for monitoring of unfractionated heparin in intensive care patientsNICE NG89 recommendations for extended pharmacological thromboprophylaxis - is it justified and is it cost effective: a rebuttal from the British Society for HaematologyAddendum to British Society for Haematology Guidelines on Investigation and Management of Antiphospholipid syndrome, 2012 (Br. J. Haematol. 2012; 157: 47-58): use of direct acting oral anticoagulantsGermline mutations in the transcription factor IKZF5 cause thrombocytopeniaPartial rescue of naturally occurring active site factor X variants through decreased inhibition by tissue factor pathway inhibitor and antithrombinThe heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healingThrombophilia in non-thrombotic chronic venous disease of the lower limb - a systematic reviewGuidelines on the laboratory aspects of assays used in haemostasis and thrombosis
P50
Q26752148-5A97182C-D279-450B-B65E-D8EFD9368E4FQ27322516-37058D58-0E8C-4C9C-B3FF-858D8DE20CF1Q33930693-D51577E8-DD54-47A6-AD67-F2C1E07293DFQ34543388-A6D8C903-CEDD-42B5-9CBF-086E4528C259Q34816051-6467B584-26B1-417B-8C18-1B753E872B78Q35897602-2FCC503A-5F97-4DB9-A5BE-CC8D5689CEA0Q38715111-5B162AB3-CF5E-4023-ADB9-52E8F9ADE377Q39305089-CD4B1BFD-90D9-45B7-AFFD-37ACD487A7A4Q44779205-814398B0-D0E9-4545-9FDE-CC87840C2F28Q45869919-95E72225-7654-46CC-B2F0-7C97EB171CE0Q45872638-F1037915-2C54-48C9-8688-867B586F997CQ45874634-70D67750-9DFA-4920-B85B-D56288CB27D0Q48937293-B94AC1DD-0212-4E24-BFF1-42ACE9EBCAB1Q52642543-2654A38A-CE22-49BA-AE8B-CE660D4C2F9DQ57789163-7E5964EF-FF78-442D-8108-9FE9ACE2D94FQ58717272-64535D6E-C82D-45D5-AA80-0C04748E486AQ60911659-DD733A1B-E84D-4355-A5FA-A60F47B8E054Q63916372-FB2D64CF-F0F5-4636-BC8C-6F47A0BE8194Q64896694-234E6560-6A29-4429-A1FA-59B738C5713BQ90261235-467AF63C-4852-4D5A-BFFD-8712F2F1B2C2Q90666659-928C8BD2-3586-4B73-813F-BFDC5EEAF07AQ90730757-D02FA211-D662-47F3-932D-DFBBD53EA8BCQ90850165-49FA6B5A-D8E3-4CE1-9673-E40FB72D3567Q91143330-620489F6-9FEC-4C3A-980A-122CBE6C0DB0Q91831253-9CD1AA83-D369-4288-879E-20FA33AB2689Q92361681-651DB639-B3D8-4B66-A220-FC130AFA26DAQ92420520-667E574E-1ECE-46F1-B2AE-8084C3132EEBQ92541313-C20CA4AD-E825-4F43-908F-B28CE2D670D6Q92553370-16BC1841-36B9-443C-8B03-EE785466BCDAQ92675465-4B7B0458-95C5-4930-B448-F04515616B70Q92882968-070DF7D3-3E03-45CF-BCC4-A0D5CDC50442Q92986959-5A7D2D25-70AF-441C-8865-088EB927D95EQ93038492-21117EB8-E320-4510-96CA-A6F8ABBFD65DQ93386206-B99D8AD3-2677-4AF9-BB85-FDA1F727D564Q96347959-3C5D83E3-88DB-46DC-B1EA-DBB8253916B8
P50
description
researcher (ORCID 0000-0002-8268-3268)
@en
name
Michael Laffan
@en
type
label
Michael Laffan
@en
prefLabel
Michael Laffan
@en
P31
P496
0000-0002-8268-3268